Replies to post #178987 on Biotech Values

[north40000]

Was the patent litigation between IDIX and GILD ever settled?

[oc631]

Thus, the fact that MRK will now own IDIX outright doesn't change the competitive outlook much for GILD.

NVS has an option license agreement for any nucleotide analog developed by IDIX which (considering the deal goes through) MRK would have to honor unless NVS agrees to changes to the original IDIX/NVS agreement. Another reason this buyout premium seems absurd.